Analytical Data
-
基因名
ADCYAP1
- Application
-
别名
Pituitary adenylate cyclase-activating polypeptide 27; PACAP-27
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P18509
-
表达区间
82-129aa
-
氨基酸序列
DVAHGILNE AYRKVLDQLS AGKHLQSLVA RGVGGSLGGG AGDDAEPLS
-
分子量
18 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ADCYAP1 (Adenylate Cyclase Activating Polypeptide 1) is a neuropeptide that plays a crucial role in various physiological processes, including neuroprotection, circadian rhythm regulation, and the modulation of anxiety and stress responses. It is primarily expressed in the nervous system and has been implicated in several neurodegenerative diseases and psychiatric disorders. Research on ADCYAP1 recombinant proteins has gained momentum as scientists aim to explore its therapeutic potential. By producing synthetic forms of this peptide, researchers can investigate its functional dynamics, receptor interactions, and signaling pathways, providing insights into its role in neuronal communication and plasticity. Furthermore, studies on ADCYAP1 can lead to the development of novel therapeutic strategies for conditions such as depression, bipolar disorder, and Alzheimer's disease. Understanding the mechanisms through which ADCYAP1 operates may also unveil new targets for drug development, highlighting the importance of this protein in the context of neurobiology and pharmacology. Overall, the development and characterization of ADCYAP1 recombinant proteins offer exciting opportunities to unravel the complexities of neuropeptide signaling and its implications for mental health and neurological disorders.
